Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Infliximab in Ankylosing Spondylitis
NCT00202865Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2005
- Primary completion
- May 2007
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 3 trial of infliximab in ankylosing spondylitis (AS), sponsored by Merck & Co.. Started May 2005; status: completed.
02
Drugs
infliximab
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT00202865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00202865.